Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBT-102
- Development stage
- Phase 1
- Lead developer
- CommBio Therapeutics
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Gene Therapies, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
CBT-102 refers to two distinct investigational drugs in development by different companies for separate indications: 1. **CBT-102/CBT102-A by CommBio Therapeutics** This is an orally administered engineered probiotic (genetically modified bacteria) expressing phenylalanine hydroxylase (PAH), designed as a gene therapy for the treatment of phenylketonuria (PKU). The engineered bacteria metabolize phenylalanine in the gut, reducing systemic levels and addressing the metabolic defect in PKU. It is currently being evaluated in Phase 1 clinical trials for children with PKU[1][2][3][4]. 2. **CBT-102 by CBT Pharmaceuticals** This is a multi-targeted small molecule kinase inhibitor with anti-cancer activity targeting VEGFR, PDGFR, MAPK, B-RAF, C-RAF, C-KIT and CSF1R. It has demonstrated preclinical efficacy against various solid tumors but does not appear to have entered clinical trials as of 2018[5]. 3. **CBT 102 by CERES BRAIN Therapeutics** Dodecyl creatine ester (also known as CBT 101), an intranasal creatine prodrug under preclinical development for Parkinson's disease; mechanism undefined[7]. The most prominent and advanced "CBT-102" is the engineered probiotic from CommBio Therapeutics for PKU.
- Other names
- CBT-102CBT102CBT 102CBT102-ACBT-102-ACBT 102-A
02
Targets
PAH (Phenylalanine hydroxylase)
Beyond the preview
Go deeper on CBT-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CBT-102.